Essential thrombocytemia and acute coronary syndrome: clinical profile and association with other thromboembolic events

References

• Bazzan M, Tamponi G, Schinco P, Vaccarino A, Foli C, Gallone G, et al. Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia. Ann Hematol. 1999; 78: 539–43
   PubMed Web of Science ®Google Scholar
• Haddad M, Veinot JP, Masters RG, Hendry PJ. Essential thrombocytosis causing a massive myocardial infarction. Cardiovasc Pathol. 2003; 12: 216–8
   PubMed Web of Science ®Google Scholar
• Turgut T, Harjai KJ, Edupuganti R, Cole J, Jenkins JS, Ramee SR, et al. Acute coronary occlusion and in-stent thrombosis in a patient with essential thrombocythemia. Cathet Cardiovasc Diagn. 1998; 45: 428–33
   PubMedGoogle Scholar
• Hamada Y, Matsuda Y, Fujii B, Ohno H, Takashiba K, Ebihara H, et al. Multiple coronary thrombosis in a patient with thrombocytosis. Clin Cardiol. 1989; 12: 723–4
   PubMedGoogle Scholar
• Esteves FA, Costa FA, Lima AA, Kajita LJ, Martinez Filho EE. Essential thrombocythemia and acute myocardial infarction treated with rescue coronary angioplasty. Arq Bras Cardiol. 1999; 73: 97–102
   PubMedGoogle Scholar
• Gul C, Kurum T, Demir M, Ozbay G, Vural O, Iqbal O, et al. Acute myocardial infarction in a patient with essential thrombocythemia treated with glycoprotein IIb/IIIa inhibitor. Clin Appl Thromb Hemost. 2004; 10: 77–9
   PubMed Web of Science ®Google Scholar
• Daya SK, Gowda RM, Landis WA, Khan IA. Essential thrombocythemia-related acute ST-segment elevation myocardial infarction. A case report and literature review. Angiology 2004; 55: 319–23
   PubMed Web of Science ®Google Scholar
• Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004; 89: 215–32
   PubMed Web of Science ®Google Scholar
• Besses C, Cervantes F, Pereira A, Florensa L, Sole F, Hernandez-Boluda JC, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 1999; 13: 150–4
   PubMed Web of Science ®Google Scholar
• Jantunen R, Juvonen E, Ikkala E, Oksanen K, Anttila P, Ruutu T. The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia. Ann Hematol. 2001; 80: 74–8
   PubMed Web of Science ®Google Scholar
• Watson KV, Key N. Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors. Br J Haematol. 1993; 83: 198–203
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990; 8: 556–62
   PubMed Web of Science ®Google Scholar
• Chim CS, Kwong YL, Lie AK, Ma SK, Chan CC, Wong LG, et al. Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med. 2005; 165: 2651–8
   PubMed Web of Science ®Google Scholar
• Schafer AI. Thrombocytosis. N Engl J Med. 2004; 350: 1211–9
   PubMed Web of Science ®Google Scholar
• van Genderen PJ, Michiels JJ, van der Poel-van de Luytgaarde SC, van Vliet HH. Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count. Ann Hematol. 1994; 69: 81–4
   PubMed Web of Science ®Google Scholar
• Schafer AI. Thrombocytosis and thrombocythemia. Blood Rev. 2001; 15: 159–66
   PubMed Web of Science ®Google Scholar
• Regev A, Stark P, Blickstein D, Lahav M. Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol. 1997; 56: 168–72
   PubMed Web of Science ®Google Scholar
• Ruggeri M, Finazzi G, Tosetto A, Riva S, Rodeghiero F, Barbui T. No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol. 1998; 103: 772–7
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995; 332: 1132–6
   PubMed Web of Science ®Google Scholar
• Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005; 353: 33–45
   PubMed Web of Science ®Google Scholar
• Barbui T, Finazzi G. When and how to treat essential thrombocythemia. N Engl J Med. 2005; 353: 85–6
   PubMed Web of Science ®Google Scholar
• Lin GM, Chao TY, Wang WB. Acute coronary syndromes and Anagrelide. Int J Cardiol. 2007; 117: e17–9
   Google Scholar